<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279745</url>
  </required_header>
  <id_info>
    <org_study_id>APD811-007</org_study_id>
    <nct_id>NCT02279745</nct_id>
  </id_info>
  <brief_title>Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension</brief_title>
  <official_title>An Open-Label Extension Study of Ralinepag in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label extension study to determine the long-term safety and&#xD;
      tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study,&#xD;
      APD811-003. Patients must have completed the APD811-003 study and must meet eligibility&#xD;
      criteria for APD811-007.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label extension study to determine the long-term safety and&#xD;
      tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 Study&#xD;
      APD811-003. Patients must have completed Study APD811-003 and met eligibility criteria for&#xD;
      Study APD811-007. Additionally, placebo-treated patients who discontinue study drug treatment&#xD;
      due to clinical worsening in Study APD811-003 will be permitted to enroll in Study&#xD;
      APD811-007, upon approval of the medical monitor, provided that all end of study procedures&#xD;
      including right heart catheterization are performed per protocol. The Week 25 Visit in Study&#xD;
      APD811-003 will serve as the Baseline Visit for Study APD811-007.&#xD;
&#xD;
      All patients enrolled in Study APD811-007 will receive open-label treatment with APD811. The&#xD;
      starting dose and titration schedule will be individually determined and in accordance with&#xD;
      the starting dose and titration schedule optimized from Study APD811-003. Adjustments in the&#xD;
      dose and titration schedule may be made according to patient tolerability.&#xD;
&#xD;
      After an individual patient completes Study APD811-003 and that patient's database is locked,&#xD;
      patient unblinding will occur. Patients on active treatment (APD811) will remain on current&#xD;
      dose and have onsite clinical assessments performed every 3 months until the patient is&#xD;
      discontinued from the study.&#xD;
&#xD;
      Patients in the placebo treatment group will undergo a dose titration period until a stable,&#xD;
      maximum tolerated dose (MTD) is reached (up to 9 weeks), followed by a treatment period after&#xD;
      the MTD is determined during which monthly onsite clinic assessments will be performed for&#xD;
      the first 3 months and then every 3 months until the patient is discontinued from the study&#xD;
      or the study is terminated (see Table 2).&#xD;
&#xD;
      Discontinuation of the study may also occur at Sponsor's decision to terminate the study.&#xD;
      Dose reductions may be made at any time for safety reasons.&#xD;
&#xD;
      Incremental dose increases will also be allowed during the Treatment Period at the discretion&#xD;
      of the investigator (as clinically indicated) and according to the stepwise titration scheme.&#xD;
      Uptitration should not occur within 6 weeks of an efficacy assessment.&#xD;
&#xD;
      Patients will be assessed for clinical worsening during each clinic visit. If clinical&#xD;
      worsening is confirmed, the Investigator may opt to either continue treatment with APD811 at&#xD;
      the current dose, increase the dose of APD811, interrupt treatment, or discontinue the&#xD;
      patient at his/her discretion.&#xD;
&#xD;
      In addition, all patients will be contacted yearly following discontinuation in Study&#xD;
      APD811-007 to assess mortality status. The mortality status follow-up contact of patients who&#xD;
      withdraw consent will depend on local regulations or specific agreement with the subject and&#xD;
      investigator.&#xD;
&#xD;
      After the last patient enrolled in Study APD811-007 has completed approximately 6 months of&#xD;
      the study, a cumulative all-patient data analysis will be performed for all patients who&#xD;
      entered the study. Patients will continue to have visits to the clinic every 3 months&#xD;
      indefinitely to collect data until marketing approval of APD811 is granted or until the&#xD;
      Sponsor discontinues the study. At the time of marketing approval or the Sponsor's decision&#xD;
      to discontinue the study, all on-going patients will complete an End of Study Visit. A 28-day&#xD;
      Follow-up Visit will be conducted to ensure appropriate subject safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">March 29, 2021</completion_date>
  <primary_completion_date type="Actual">March 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety assessed by adverse events up to 28 days following discontinuation of study drug</measure>
    <time_frame>From Baseline to 28 days following discontinuation of study drug.</time_frame>
    <description>The number of adverse events will be computed overall and by treatment group in the parent study (Study APD811-003)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Ralinepag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ralinepag immediate release (IR) capsules of 0.01, 0.02, 0.03, 0.04 mg, and 0.10 mg per capsule or extended release (XR) tablets of 50, 250, and 400 mcg (0.05, 0.25 and 0.4 mg) for oral administration. The starting dose and titration schedule will be determined for each subject in accordance with the starting dose and titration schedule optimized from Study APD811-003.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ralinepag</intervention_name>
    <description>Active</description>
    <arm_group_label>Ralinepag</arm_group_label>
    <other_name>APD811</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document&#xD;
&#xD;
          -  Is willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures and is deemed an appropriate candidate for participation in&#xD;
             a long-term extension study and administration of APD811&#xD;
&#xD;
               -  Fulfilled all eligibility criteria for APD811-003 and completed the study as&#xD;
                  planned&#xD;
&#xD;
               -  Patients who discontinued for clinical worsening in APD811-003 and were assigned&#xD;
                  to placebo and completed all end of study procedures including right heart&#xD;
                  catheterization (RHC) may participate after their data from the APD811-003 study&#xD;
                  is cleaned and locked&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who enrolled in APD811-003 and were withdrawn from study drug treatment due&#xD;
             to any AE, SAE, or clinical worsening if assigned to APD811, or patients who did not&#xD;
             complete the APD811 003 study for other reasons.&#xD;
&#xD;
          -  Female patients who wish to become pregnant&#xD;
&#xD;
          -  Systolic BP &lt;90 mmHg at Baseline/Day 1&#xD;
&#xD;
          -  Other severe acute or chronic medical or laboratory abnormality that may increase the&#xD;
             risk associated with study participation or investigational product administration or&#xD;
             may interfere with the interpretation of study results and, in the judgment of the&#xD;
             investigator, would make the patient inappropriate for entry into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cardiac and Vascular Center, Anschutz Inpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Medicine Associates</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center General Clinical Research Unit (GCRU)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center - Martha Morehouse Medical Pavilion</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC, Presbytarian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital/Lung Transplant Unit</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment in Cardiology EAD, Department of Cardiology</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;National Heart Hospital&quot; EAD, Clinic of Cardiology</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot; St. Anna&quot;, Sofia AD, Cardiology Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1750</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine I - Cardiology, University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Internal Clinic - Clinic of Cardiology and Angiology, 1st Faculty of Medicine, Charles University in Prague, General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy Orszagos Kardiológiai lntézet National Institute of Cardiology, Department of Adult Cardiology</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Department of Pulmonology - Semmelweis Egyetem Pulmonológiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Derecen Clinical Research Center Cardiology and Cardiac Surgery Department - Debreceni Egyetem Klinikai Kozpont Kardiologiai es Szivsebeszeti Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs, Medical School, Heart Institute - Pécsi Tudományegyetem, Klinikai Központ, Szívgyógyászati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged Faculty of Medicine, 2nd Department of Medicine and Cardiology Center, Albert Szent-Györyi Clinical Center - SZTE ÁOK Szent-Györgyi A lbert Klinikai Központ I I. sz. Belgyógyászati Klini ka és Kard ilógiai Központ</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Bialystok Clinical Hospital Cardiology Clinic - Uniwersytecki Szpital Kliniczny, Klinika Kardiologii z Oddziałem Intensywnego Nadzoru Kardiologicznego</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Paul II Hospital in Cracov Department of Cardiac and Vascular Diseases - Krakowski Szpital Specjalistyczny im. Jana Pawła II, Oddział Kliniczny Chorób Serca i Naczyń</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biegański Provincial Specialist Hospital Department of Cardiology - Wojewódzki Szpital Specjalistyczny im. dr Wł. Biegańskiego w Lodzi, Oddział Kardiologiczny</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Prof. Dr. C.C. Iliescu&quot; Institute of Cardiovascular Diseases, Department of Clinic Cardiology III - Institutul de Urgenţă pentru Boli Cardiovasculare &quot;Prof. Dr. C.C. Iliescu&quot;, Secţia Clinica Cardiologie fIJ</name>
      <address>
        <city>Bucharest</city>
        <zip>022322</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Marius Nasta&quot; Institute of Pneumoftiziology, Department of Pneumoftiziology IV - Institutul de Pneumoftiziologie &quot;Marius Nasta&quot;, Sectia Clinica Pneumoftiziologie IV</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. Victor Babes&quot; Clinic Hospital for Infesctious Diseases and Pneumoftiziology, Department of Clinic Pneumology II</name>
      <address>
        <city>Timisoara</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia (CCS), Cardiology Clinic - Klinicki Centar SrЬije, Klinika za kardiologiju</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Кlinjcko-bolnicki centar Zemun, Кlinika za internu medicmu, Sluzba za kardiologiju</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Pulmonary Diseases of Vojvodina Sremska Kamenica (IPDVSK), The Clinic for Urgent Pulmonology, ICU - Intensive Care Unit - Klinicki Centar SrЬije, Klinika za kardiologiju</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Heart Failure and Transplantation, National Institute of Cardiovascular Diseases - Oddelenie zlyhávania a transplantácie srdca, Národný ústav srdcových a cievnych chorôb, a.s.</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology department, East Slovak Institute for Cardiovascular Diseases - Kardiologické oddelenie Klinika kardiológie , Východoslovenský ústav srdcových a cievnych chorôb, a.s</name>
      <address>
        <city>Košice</city>
        <zip>4011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Universitary Hospital Vall d'Hebron, Department of Pneumology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Hospital of Barcelona, Department of Pneumology</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12th of October, Department of Cardiology</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 25, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 20, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

